Johnson Mahlon D, Floyd John L, Caprioli Richard M
Department of Pathology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
J Neuropathol Exp Neurol. 2006 Sep;65(9):837-45. doi: 10.1097/01.jnen.0000235116.67558.24.
In the "postgenome" era, attention has turned to the proteome as a source of complementary diagnostic and prognostic information. Recent advances in imaging mass spectrometry (IMS) uses matrix-assisted laser desorption ionization-mass spectrometry (MALDI-MS) to acquire up to 1,000 individual protein signals within the molecular weight range of 2,000 to over 100,000 in specific areas of tissue sections. The systematic investigation of these sections permits creation of specific molecular weight images (ion density maps) for each signal detected. Analysis of these images can reveal a collection of unique protein changes, or a "protein signature", of diagnostic and prognostic value. These signatures may also afford assessment of disease progression and tissue response to treatments. Combined with histology and molecular genetic analyses, new proteomic techniques should refine subclassifications and provide defining information about the pathogenesis of many central and peripheral nervous system diseases.
在“后基因组”时代,人们的注意力已转向蛋白质组,将其作为补充诊断和预后信息的来源。成像质谱(IMS)的最新进展利用基质辅助激光解吸电离质谱(MALDI-MS)在组织切片的特定区域获取分子量范围在2000至超过100000之间的多达1000个单个蛋白质信号。对这些切片进行系统研究可针对每个检测到的信号创建特定的分子量图像(离子密度图)。对这些图像的分析可以揭示具有诊断和预后价值的独特蛋白质变化集合,即“蛋白质特征”。这些特征还可以评估疾病进展和组织对治疗的反应。与组织学和分子遗传学分析相结合,新的蛋白质组学技术应能完善疾病亚分类,并提供有关许多中枢和外周神经系统疾病发病机制的决定性信息。